A biotechnology company, Amyris, has received approval to settle a $15.1 million case with a cannabinoid manufacturer, Lavvan. A Delaware bankruptcy judge passed the verdict, effectively resolving a multi-year litigation and arbitration battle stemming from allegations that Amyris misused the trade secrets of Lavvan, its former business associate.
Involved in the protractedd legal dispute were accusations against Amyris of expropriating Lavvan’s proprietary information. However, the recent settlement finally brings a favorable resolution to the lengthy legal case.
For more detailed information on this case, readers are encouraged to review the court proceedings directly from the original report located at the Law360 website.